A new drug for Psoriasis, Ixekizumab, is receiving a lot of media attention as of late. The Savin Center is currently testing this drug.
The manufacturer of this new drug, Eli Lilly, issued a press release on their clinical trials and found that this new drug cleared skin in one-third of patients. Eli Lilly stated that “78-90% of the patients taking ixekizumab experienced at least a 75% improvement in their psoriasis after twelve weeks, as measured by the Psoriasis Area and Severity Index (PASI 75). Of these patients, 31-41% achieved 100% improvement (PASI 100) after 12 weeks, which is clear skin”.
The Savin Center is currently seeking volunteers for several studies. Please call our office for more information.
The Savin Center is also studying a new treatment for psoriasis, a biosimilar medication that can be compared to Enbrel. The Savin Center has piloted some of the most revolutionary clinical research and skincare trials of the last 50 years. In addition to testing treatments for Psoriasis, the Savin Center has tested Accutane, BOTOX®, Propecia® and Rogaine® as well.
The Savin Center is enrolling patients for a new treatment for Psoriasis. Although Psoriasis is a chronic disease, there are specific medications and lifestyle changes that one can take in order to keep symptoms controlled. The Savin Center team works with our New Haven patients to identify appropriate steps that one needs to take in order to have clear skin.
To schedule your psoriasis consultation, or to learn more about our upcoming clinical trial, call The Savin Center today.